Article
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.
Anticancer research - 1 May 2023
Gordon Erlinda M, Angel Nicole L, Omelchenko Nadezhda, Chua-Alcala Victoria S, Moradkhani Ania, Quon Doris, Wong Steven
Abstract excerpt
BACKGROUND/AIM: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in various types of cancer. We aimed to determine the safety and efficacy of mTOR inhibitor nab-sirolimus when combined with the immune checkpoint inhibitor nivolumab. PATIENTS AND METHODS: Previously treated patients ≥18 years with confirmed diagnosis of advanced sarcoma or tumor with mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.